Provided by Tiger Fintech (Singapore) Pte. Ltd.

Esperion Therapeutics

0.9297
+0.07779.12%
Post-market: 0.93290.0032+0.34%19:56 EDT
Volume:3.98M
Turnover:3.52M
Market Cap:183.94M
PE:-3.36
High:0.9500
Open:0.8800
Low:0.8201
Close:0.8520
Loading ...

Esperion Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
04 Mar

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
04 Mar

Esperion Therapeutics Shares Rise on 4Q Revenue Growth

Dow Jones
·
04 Mar

Esperion Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
04 Mar

Esperion Expects Full Year 2025 Operating Expenses Of $215M-$235M, Including Approximately $15M In Non-cash Expenses Related To Stock Compensation

Benzinga
·
04 Mar

Esperion Therapeutics Q4 2024 GAAP EPS $(0.11) Beats $(0.16) Estimate, Sales $69.11M Beat $61.58M Estimate

Benzinga
·
04 Mar

BRIEF-Esperion Therapeutics Q4 Basic EPS USD -0.11

Reuters
·
04 Mar

Esperion Therapeutics Q4 Net Income USD -21.318 Million

THOMSON REUTERS
·
04 Mar

Esperion Therapeutics Inc - Q4 Total Revenue Grew 114% to $69.1 Million

THOMSON REUTERS
·
04 Mar

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
04 Mar

Esperion partners with CSL Seqirus to commercialize NEXLETOL, NEXLIZET

TIPRANKS
·
03 Mar

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

GlobeNewswire
·
03 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?

Insider Monkey
·
01 Mar

Esperion Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
28 Feb

Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
26 Feb

Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know

Zacks
·
25 Feb

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

GlobeNewswire
·
18 Feb

BRIEF-Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
14 Feb

Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
14 Feb